Original Contributions |
-Inducible Genes, Lower Triglycerides, and Raise HDL Levels In Vivo
From the Departments of Pharmacology (R.M., L.J., P.H., J.R.P.), Drug Safety and Disposition (J.S.), and Retinoid Research (R.A.H.), Ligand Pharmaceuticals, Inc, San Diego, Calif.
Correspondence to Ranjan Mukherjee, Department of Pharmacology, Ligand Pharmaceuticals, Inc, 10255 Science Center Drive, San Diego, CA 92121. E-mail rmukherjee{at}ligand.com
AbstractPeroxisome
proliferatoractivated receptors (PPARs) and retinoid X
receptors (RXRs) are members of the intracellular receptor superfamily.
PPARs bind to peroxisome proliferatorresponse elements (PPREs) as
heterodimers with RXR and as such activate gene transcription
in response to activators. Fibrates like gemfibrozil are
well-known PPAR
activators and are used in the treatment
of hyperlipidemia. We show that the RXR ligand LGD1069
(Targretin(TM)), like gemfibrozil, can
activate the PPAR
/RXR signal-transduction pathway, including
transactivation of the bifunctional enzyme or acyl-CoA oxidase response
elements in a cotransfection assay. The activation also occurs in vivo,
whereby in rats treated with LGD1069 or gemfibrozil, bifunctional
enzyme and acyl-CoA oxidase RNA are induced and the combination of
LGD1069 and gemfibrozil leads to a greater induction. Importantly, in
hypertriglyceridemic db/db
mice treated with RXR or PPAR
agonists, triglyceride
levels are lowered, and the combination again has significantly greater
efficacy. RXR agonists also raise HDL cholesterol levels
without changing apoA-I RNA expression. This observation suggests the
use of RXR-selective agonists, "rexinoids," either alone or in
combination with a fibrate as a new therapeutic approach to treating
patients with high triglyceride and low HDL
cholesterol levels.
Key Words: RXR PPAR rexinoids hypertriglyceridemia low HDL
This article has been cited by other articles:
![]() |
J. de Vries-van der Weij, W. de Haan, L. Hu, M. Kuif, H. L. D. W. Oei, J. W. A. van der Hoorn, L. M. Havekes, H. M. G. Princen, J. A. Romijn, J. W. A. Smit, et al. Bexarotene Induces Dyslipidemia by Increased Very Low-Density Lipoprotein Production and Cholesteryl Ester Transfer Protein-Mediated Reduction of High-Density Lipoprotein Endocrinology, May 1, 2009; 150(5): 2368 - 2375. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Desvergne, L. Michalik, and W. Wahli Transcriptional Regulation of Metabolism Physiol Rev, April 1, 2006; 86(2): 465 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Harrity, D. Farrelly, A. Tieman, C. Chu, L. Kunselman, L. Gu, R. Ponticiello, M. Cap, F. Qu, C. Shao, et al. Muraglitazar, a Novel Dual ({alpha}/{gamma}) Peroxisome Proliferator-Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves {beta}-Cell Function in db/db Mice Diabetes, January 1, 2006; 55(1): 240 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Anderson, C. Dunn, A. Laughter, L. Yoon, C. Swanson, T. M. Stulnig, K. R. Steffensen, R. A.S. Chandraratna, J.-A. Gustafsson, and J. C. Corton Overlapping Transcriptional Programs Regulated by the Nuclear Receptors Peroxisome Proliferator-Activated Receptor {alpha}, Retinoid X Receptor, and Liver X Receptor in Mouse Liver Mol. Pharmacol., December 1, 2004; 66(6): 1440 - 1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fischer, S. M. G. Dias, M. A. M. Santos, A. C. Alves, N. Zanchin, A. F. Craievich, J. W. Apriletti, J. D. Baxter, P. Webb, F. A. R. Neves, et al. Low Resolution Structures of the Retinoid X Receptor DNA-binding and Ligand-binding Domains Revealed by Synchrotron X-ray Solution Scattering J. Biol. Chem., April 25, 2003; 278(18): 16030 - 16038. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Repa, K. E. Berge, C. Pomajzl, J. A. Richardson, H. Hobbs, and D. J. Mangelsdorf Regulation of ATP-binding Cassette Sterol Transporters ABCG5 and ABCG8 by the Liver X Receptors alpha and beta J. Biol. Chem., May 17, 2002; 277(21): 18793 - 18800. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Ahuja, S. Liu, D. L. Crombie, M. Boehm, M. D. Leibowitz, R. A. Heyman, C. Depre, L. Nagy, P. Tontonoz, and P. J. A. Davies Differential Effects of Rexinoids and Thiazolidinediones on Metabolic Gene Expression in Diabetic Rodents Mol. Pharmacol., April 1, 2001; 59(4): 765 - 773. [Abstract] [Full Text] |
||||
![]() |
P. J. A. Davies, S. A. Berry, G. L. Shipley, R. H. Eckel, N. Hennuyer, D. L. Crombie, K. M. Ogilvie, J. Peinado-Onsurbe, C. Fievet, M. D. Leibowitz, et al. Metabolic Effects of Rexinoids: Tissue-Specific Regulation of Lipoprotein Lipase Activity Mol. Pharmacol., February 1, 2001; 59(2): 170 - 176. [Abstract] [Full Text] |
||||
![]() |
J. J. Repa, S. D. Turley, J.-M. A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. Shan, R. A. Heyman, J. M. Dietschy, and D. J. Mangelsdorf Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers Science, September 1, 2000; 289(5484): 1524 - 1529. [Abstract] [Full Text] |
||||
![]() |
G. Shao, R. A. Heyman, and I. G. Schulman Three Amino Acids Specify Coactivator Choice By Retinoid X Receptors Mol. Endocrinol., August 1, 2000; 14(8): 1198 - 1209. [Abstract] [Full Text] |
||||
![]() |
S. M. Lippman and R. Lotan Advances in the Development of Retinoids as Chemopreventive Agents J. Nutr., February 1, 2000; 130(2): 479 - 479. [Abstract] [Full Text] |
||||
![]() |
E. D. Bischoff, R. A. Heyman, and W. W. Lamph Effect of the Retinoid X Receptor-Selective Ligand LGD1069 on Mammary Carcinoma After Tamoxifen Failure J Natl Cancer Inst, December 15, 1999; 91(24): 2118 - 2118. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Knoblauch, A. Busjahn, B. Muller-Myhsok, H.-D. Faulhaber, H. Schuster, R. Uhlmann, and F. C. Luft Peroxisome Proliferator-Activated Receptor {gamma} Gene Locus Is Related to Body Mass Index and Lipid Values in Healthy Nonobese Subjects Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2940 - 2944. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Desvergne and W. Wahli Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism Endocr. Rev., October 1, 1999; 20(5): 649 - 688. [Abstract] [Full Text] |
||||
![]() |
S. I. Sherman, J. Gopal, B. R. Haugen, A. C. Chiu, K. Whaley, P. Nowlakha, and M. Duvic Central Hypothyroidism Associated with Retinoid X Receptor-Selective Ligands N. Engl. J. Med., April 8, 1999; 340(14): 1075 - 1079. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Berger, M. D. Leibowitz, T. W. Doebber, A. Elbrecht, B. Zhang, G. Zhou, C. Biswas, C. A. Cullinan, N. S. Hayes, Y. Li, et al. Novel Peroxisome Proliferator-activated Receptor (PPAR) gamma and PPARdelta Ligands Produce Distinct Biological Effects J. Biol. Chem., March 5, 1999; 274(10): 6718 - 6725. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ribalta, J. Girona, J. C. Vallvé, A. E. La Ville, M. Heras, and L. Masana Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia J. Lipid Res., March 1, 1999; 40(3): 426 - 431. [Abstract] [Full Text] |
||||
![]() |
P. Costet, C. Legendre, J. More, A. Edgar, P. Galtier, and T. Pineau Peroxisome Proliferator-activated Receptor alpha -Isoform Deficiency Leads to Progressive Dyslipidemia with Sexually Dimorphic Obesity and Steatosis J. Biol. Chem., November 6, 1998; 273(45): 29577 - 29585. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |